European Psychiatry - Volume 33 - March 2016

378 / 812

S374 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
to them which can end with serious consequences. Online forum
content gives us a strong base understanding of users experiences
of SC. Further research is required to elucidate a more nuanced
understanding.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV75
The “Endless Trip”: Psychopathology
and psychopharmacology in the
Hallucinogen Persisting Perception
Disorder (HPPD)
L. Orsolini ∗, A. Valchera , D. Papanti , R. Vecchiotti ,
D. De Berardis
1 Villa San Giuseppe Hospital- Hermanas Hospitalarias, Department
of Psychiatry, Ascoli Piceno, Italy
2 Villa San Giuseppe Hospital, Department of Psychiatry, Ascoli
Piceno, Italy
3 University of Hertfordshire, Department of Pharmacy, Hatfield,
United Kingdom
4 Hospital “G. Mazzini” – ASL 4, NHS – Department of Mental Health
– Psychiatric Service of Diagnosis and Treatment, Teramo, Italy
∗ Corresponding author.
Introduction Hallucinogen Persisting Perception Disorder
(HPPD) is a syndrome characterized by prolonged or reoccur-
ring perceptual symptoms, reminiscent of acute hallucinogen
effects. HPPD was associated with a broader range of LSD (lysergic
acid diethylamide)-like substances, including cannabis, MDMA
(methylenedioxymethamphetamine), psilocybin, mescaline and
other psychostimulants. Symptomatology mainly comprises visual
disorders (i.e., geometric pseudo-hallucinations, halos, flashes of
colours/lights, motion-perception deficits, afterimages, micropsy,
more acute awareness of floaters, etc.), even though depressive
symptoms and thought disorders may be comorbidly present.
Objective Although HPPD was firstly described in 1954, it was
definitely established as a syndrome in 2000 with the revised
forth version of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR). However, neuronal substrate, risk factors,
aetiology and pathogenesis of HPPD remains still unknown and
under investigation. Furthermore, there are still open questions
about its pharmacological targets.
Aims A critical review on psychopathological bases, etiological
hypothesis and psychopharmacological approaches towards HPPD
was here provided.
Methods A systematic literature search on PubMed/Medline,
GoogleScholar and Scopus databases without time restrictions, by
using a specific set of keywords was here carried out. In addition, a
case report was here described.
Results and conclusions Pharmacological and clinical issues are
here considered and practical psychopharmacological recommen-
dations and clinical guidelines here suggested.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV76
Psychosis and polydrug abuse in a
patient with Dandy-Walker variant
L. Orsolini ∗, A. Valchera , R. Vecchiotti ,
M. Panichi , D. De Berardis
1 Villa San Giuseppe Hospital – Hermanas Hospitalarias, Department
of Psychiatry, Ascoli Piceno, Italy
2 Maastricht University, Department of Psychiatry and
Neuropsychology, Maastricht, Netherlands
3 School of Life and Medical Sciences- University of Hertfordshire,
Department of Pharmacy, Hatfield, United Kingdom
4 Polyedra, Polyedra Research, Teramo, Italy
5 Ital “G. Mazzini” – ASL 4 Teramo, NHS – Department of Mental
Health, Psychiatric Service of Diagnosis and Treatment, Teramo, Italy
6 University of “G. D’Annunzio”, Department of Neuroscience –
Imaging and Clinical Science, Chieti, Italy
∗ Corresponding author.
Background and purpose Dandy Walker “syndrome” (DWS) was
firstly defined by Dandy and Blackfan, and then described by
Hart et al. [1] as a series of neurodevelopmental anomalies in
the posterior fossa, including Dandy-Walker (DW) malformation,
DW variant (cerebellar hypoplasia/aplasia of the cerebellar vermis
and cystic dilatation of the fourth ventricle), mega-cisterna magna
and posterior fossa arachnoid cyst. Mental symptoms have been
associated with DWS in previous reports, but the spectrum of men-
tal symptomatology widely varies between clinical cases, ranging
from psychotic/schizophrenia-like to mood/cognitive symptoms
[2].
Methods Here we describe a case of psychosis and polydrug
abuse in a 27-year-old man with DW variant a 4-year history of
polydrug abuse, sporadic alcohol abuse, epilepsy and psychotic
symptoms including delusions of reference/persecution, suspi-
ciousness, associated with obsessive thoughts, mood lability and
persistent anxiety.
Results He was recovered for a 28-day program of detoxifica-
tion from drug addiction/stabilization of psychiatric symptoms.
Family history of Bipolar Disorder, gambling disorder (father)
and depression (mother). The mental status examination at
baseline revealed slowness of thought, psychomotor retardation,
aboulia/anhedonia/apathy/hypomimic facies/asthenia/social with-
drawal/deflected mood/poor thought content/blunted affect/self-
neglect/poor insight, cognitive impairment and oppositive and
partially collaborative attitude and behaviour. Borderline intel-
ligence activity was found on WAIS-R (IQ = 79). At the baseline,
he was taking carbamazepine 400mg BID (baseline serum level:
6.720 g/ml), gabapentin (400mg BID), paroxetine (20mg/d),
olanzapine (10mg/d) and methadone (70ml/d), with a poor
response/control both on psychotic and seeking drug symptoma-
tology.
References not available.
Conclusions Further DWS clinical cases should be evaluated in
order to better investigate the role of this variant to addictive and
psychotic symptoms.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV77
Improved drug-use patterns at six
months post discharge from inpatient
substance use disorder treatment;
results from compulsory and
voluntary admitted patients
A. Pasareanu ∗, J.K. Vederhus , O. Kristensen , T. Clausen , A. Opsal
Sørlandet Hospital Kristiansand, Addiction Unit, Kristiansand,
Norway
∗ Corresponding author.
Background The Norwegian Municipal Health Care Act opens for
mandated treatment for persons with severe and life-threatening
substance use disorder. This study aims to examine substance use
related outcomes at six-month following in-patient treatment and
to analyse factors associated with improved outcomes and absti-
nence.
Method This prospective study followed 202 hospitalised
patients with SUD that were admitted voluntarily (n = 137) or